Reproductive Health Planning for Patients with Multiple Sclerosis: A Clinician’s Guide

Reproductive Health Planning for Patients with Multiple Sclerosis: A Clinician’s Guide

Publication date: Dec 12, 2019

This activity is designed to meet the educational needs of physicians, nurses and nurse midwives, advanced practice clinicians, and pharmacists, who manage patients with multiple sclerosis (MS).

Multiple sclerosis (MS) has a female predominance of approximately 3 to 1 and appears to be increasing among young women who are of reproductive age at the time of diagnosis. The impact of the disease and its treatment on the health of a pregnant mother and the developing fetus is a critical issue. While it may seem prudent to recommend that women discontinue disease-modifying therapy (DMT) before pregnancy or if a pregnancy is confirmed, this decision must be made on a case-by-case basis. Healthcare professionals require the latest information about DMT use during pregnancy, including available data on approved therapies and labeling recommendations that may influence this decision-making process.

Commercial Support Acknowledgement

This webinar is supported by an educational grant from Bayer HealthCare Pharmaceuticals

Valid for Credit Through: December 31, 2020

For more information please visit https://cmscscholar.org/reproductive-health-planning

Concepts Keywords
Bayer HealthCare Pregnancy
DMT Reproductive health
Fetus Multiple sclerosis
Multiple Sclerosis Articles
Pregnancy Health
Reproductive Health Midwifery
Webinar MS
Disease
Health professional
Nurse midwife

Semantics

Type Source Name
disease MESH Multiple Sclerosis
disease MESH diagnosis
disease MESH fetus
drug DRUGBANK Dimethyltryptamine

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *